Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omeza Complete Matrix (OCM™) is a drug-device combination product developed by Omeza for the management of chronic and acute wounds. The product consists of a matrix of hydrolyzed fish collagen peptides infused with cod liver oil, which acts as an anhydrous skin protectant, along with other plant-derived oils and waxes. OCM™ is designed to conform to the wound bed and provide a protective environment that supports the natural healing process by addressing multiple phases of wound repair, including biofilm management, inflammation reduction, and tissue remodeling. It is absorbable, biodegradable, and supplied in single-use vials for topical application. The product has received FDA 510(k) clearance for various indications, including diabetic, venous, and pressure ulcers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Omeza Complete Matrix.